Literature DB >> 20686377

Contribution of ultrasonography to endometrial cancer screening in patients with hereditary nonpolyposis colorectal cancer/Lynch syndrome.

Fabrice Lécuru1, Cyrille Huchon, Ulrike Metzger, Anne Sophie Bats, Marie Aude Le Frère Belda, Sylviane Olschwang, Pierre Laurent Puig.   

Abstract

OBJECTIVES: Screening for endometrial cancer is recommended in women at risk for hereditary nonpolyposis colorectal cancer/Lynch syndrome. No screening tool has been validated. The objective of this study was to assess the performance of ultrasonography used to screen for atypical hyperplasia and cancer in women at risk for hereditary nonpolyposis colorectal cancer/Lynch syndrome. Endometrial biopsy was the reference standard.
MATERIALS AND METHODS: Of 85 women with mismatch repair gene mutations or Amsterdam II criteria who were studied prospectively at our institution, 58 had 96 paired ultrasound-biopsy evaluations and were included in the study. Transvaginal or transabdominal ultrasonographic finding was considered normal if no polyps or intrauterine abnormalities were seen and if the maximum endometrial thickness was less than 4 mm in postmenopausal women not receiving hormonal replacement therapy or less than 6 mm in other women. Endometrial biopsy results were categorized as not interpretable, normal, or showing atypical hyperplasia or cancer. Sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratio of ultrasonography were computed.
RESULTS: The 58 patients had a mean age of 42.5 years and a median follow-up duration of 51.4 months (range, 17-106 months; 246 patient exposure years). Cancer was diagnosed in 2 patients. Ultrasonography had 100% sensitivity and 100% negative predictive value, 2.2 positive likelihood ratio, and 0 negative likelihood ratio. No interval cancers occurred.
CONCLUSIONS: Ultrasonography had high sensitivity and an excellent negative likelihood ratio in this study. Further studies are needed, and ultrasonography should be compared with clinical follow-up, diagnostic hysteroscopy, or endometrial biopsy alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686377     DOI: 10.1111/IGC.0b013e3181d7283a

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome.

Authors:  Matthew B Yurgelun; Rowena Mercado; Margery Rosenblatt; Monica Dandapani; Wendy Kohlmann; Peggy Conrad; Amie Blanco; Kristen M Shannon; Daniel C Chung; Jonathan Terdiman; Stephen B Gruber; Judy E Garber; Sapna Syngal; Elena M Stoffel
Journal:  Gynecol Oncol       Date:  2012-08-29       Impact factor: 5.482

2.  Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer.

Authors:  Kenta Masuda; Kouji Banno; Megumi Yanokura; Yusuke Kobayashi; Iori Kisu; Arisa Ueki; Asuka Ono; Nana Asahara; Hiroyuki Nomura; Akira Hirasawa; Nobuyuki Susumu; Daisuke Aoki
Journal:  Mol Biol Int       Date:  2011-12-08

3.  Pain evaluation during gynaecological surveillance in women with Lynch syndrome.

Authors:  Jorien Helder-Woolderink; Geertruida de Bock; Harry Hollema; Magda van Oven; Marian Mourits
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

4.  Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review.

Authors:  Natalie Lim; Martha Hickey; Graeme P Young; Finlay A Macrae; Christabel Kelly
Journal:  Int J Gynecol Cancer       Date:  2022-05-03       Impact factor: 4.661

5.  Utility of endometrial sampling prior to risk-reducing hysterectomy in a patient with Lynch syndrome.

Authors:  Melissa K Frey; Gizelka David-West; Khushbakhat R Mittal; Franco M Muggia; Bhavana Pothuri
Journal:  Ecancermedicalscience       Date:  2016-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.